Abstract
The quality control of the data and instruments on the analysis of drugs by mass spectrometry should be controlled by analytical section of pharmaceutical company. ICH, FDA, EMEA, and Ministry of Health and Welfare guidelines related the criteria of quality control of analytical method have been published. The purity and stability of the drugs are analyzed according to Validation of Analytical Procedures (ICH, 1994.10). The clinical pharmacokinetics samples are analyzed according to Guidance for Industry; Bioanalytical Methods Validation for Human Studies (FDA, 1998.12). Toxicokinetics samples are analyzed according to Validation of Analytical Procedures for toxicokinetics (Japan Pharmaceutical Manufacturers Association (JPMA), 1997.3). In this report, I write the actual quality control of analytical instrument and procedure by mass spectrometry in the pharmaceutical companies and compare the above described guideline.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
